Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Photodynamic Therapy for Preventing Recurrent Chromogenic Stains on Deciduous Teeth

NCT07736339 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-07-30

Condition(s) studied

Chromogenic Extrinsic Tooth Stains

Investigational drug(s) / intervention(s)

Antimicrobial Photodynamic TherapyConventional Prophylaxis

Antimicrobial Photodynamic Therapy: Conventional prophylaxis followed by topical application of methylene blue activated by 660-nm red light for antimicrobial photodynamic therapy.

Conventional Prophylaxis: Standard mechanical prophylaxis using rubber-cup polishing and prophylaxis paste.

Study summary

Chromogenic extrinsic stains are common in children and frequently recur following conventional prophylaxis. Antimicrobial photodynamic therapy (aPDT) using methylene blue activated by red light has demonstrated antimicrobial activity against oral biofilm and may reduce stain recurrence. This pilot controlled clinical trial aims to compare conventional prophylaxis combined with methylene blue-mediated antimicrobial photodynamic therapy with conventional prophylaxis alone for preventing recurrent chromogenic extrinsic stains on deciduous teeth.

Eligibility

Sex
ALL
Min age
4 Years
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged 4 to 6 years with chromogenic extrinsic stains affecting deciduous teeth. * Medically healthy children (ASA I or II). * Children with cooperative behavior suitable for routine dental treatment. * Parent or legal guardian willing to provide written informed consent. * Ability to attend all scheduled follow-up visits. Exclusion Criteria: * Known allergy or hypersensitivity to methylene blue. * Photosensitivity disorders or current use of photosensitizing medications. * Extensive untreated dental caries or acute dental infection requiring emergency treatment. * Gingival or periodontal conditions that interfere with clinical assessment. * Iron-associated extrinsic staining. * Children unable to comply with study procedures or follow-up visits.

Primary outcome measure(s)

  • Recurrence of Chromogenic Extrinsic Stains — 6 months after treatment
    Recurrence of chromogenic extrinsic stains assessed by standardized clinical visual examination and recorded as the presence or absence of visible chromogenic extrinsic staining at the 6-month follow-up visit.

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Cairo Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07736339 on ClinicalTrials.gov ↗ ← All trials in Egypt